FDA approves Sarepta rival NS Pharma’s Duchenne drug

Drug approved for patients with exon 53 mutation. Japanese pharma Nippon Shinyaku (NS Pharma) has scored US Food and Drug Administration (FDA) approval for its Duchenne muscular dystrophy drug viltolarsen, now

FDA sets Q3 decision date for NS Pharma’s DMD drug

NS Pharma and its parent company Nippon Shinyaku are currently enrolling patients for a phase 3 study in Japan and the US – named RACER53.

Wave’s challenge to Sarepta in Duchenne falls flat

The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD.

Solid Bio falls as FDA halts DMD trial over safety concerns

In the meantime, rival candidate viltolarsen from Japanese pharma Nippon Shinyaku (NS Pharma) has been  filed with the FDA for the treatment of DMD.

1 2 3 4 [ Next 5 results ]